Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Corneal Collagen Crosslinking to Increase the Resistance of the Support Graft of the KPro Type I Against Corneal Melting (CXL-KPro)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03041883
Recruitment Status : Recruiting
First Posted : February 3, 2017
Last Update Posted : July 17, 2020
Sponsor:
Collaborators:
Centre hospitalier de l'Université de Montréal (CHUM)
Maisonneuve-Rosemont Hospital
Information provided by (Responsible Party):
Marie-Claude Robert, Centre hospitalier de l'Université de Montréal (CHUM)

Tracking Information
First Submitted Date  ICMJE January 25, 2017
First Posted Date  ICMJE February 3, 2017
Last Update Posted Date July 17, 2020
Actual Study Start Date  ICMJE January 4, 2017
Estimated Primary Completion Date January 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 1, 2017)
  • Examine whether the use of crosslinked cornea decreases the rate of corneal melting post-Kpro when compared to using a standard corneal button [ Time Frame: 1 day ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Examine whether the use of crosslinked cornea decreases the rate of corneal melting post-Kpro when compared to using a standard corneal button [ Time Frame: 1 week ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Examine whether the use of crosslinked cornea decreases the rate of corneal melting post-Kpro when compared to using a standard corneal button [ Time Frame: 2 weeks ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Examine whether the use of crosslinked cornea decreases the rate of corneal melting post-Kpro when compared to using a standard corneal button [ Time Frame: 1 month ]
    This visits will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Examine whether the use of crosslinked cornea decreases the rate of corneal melting post-Kpro when compared to using a standard corneal button [ Time Frame: 1 month ]
    An imaging allowing quantification of the thickness of the cornea graft-support (optical coherence tomography anterior segment) will be performed.
  • Examine whether the use of crosslinked cornea decreases the rate of corneal melting post-Kpro when compared to using a standard corneal button [ Time Frame: 3 months ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Examine whether the use of crosslinked cornea decreases the rate of corneal melting post-Kpro when compared to using a standard corneal button [ Time Frame: Every 2-4 months depending on the judgment of the surgeon for at least 5 years ]
    These visits will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Examine whether the use of crosslinked cornea decreases the rate of corneal melting post-Kpro when compared to using a standard corneal button [ Time Frame: 1 year ]
    An imaging allowing quantification of the thickness of the cornea graft-support (optical coherence tomography anterior segment) will be performed.
  • Examine whether the use of crosslinked cornea decreases the rate of corneal melting post-Kpro when compared to using a standard corneal button [ Time Frame: 2 years ]
    An imaging allowing quantification of the thickness of the cornea graft-support (optical coherence tomography anterior segment) will be performed.
  • Examine whether the use of crosslinked cornea decreases the rate of corneal melting post-Kpro when compared to using a standard corneal button [ Time Frame: 5 years ]
    An imaging allowing quantification of the thickness of the cornea graft-support (optical coherence tomography anterior segment) will be performed.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 1, 2017)
  • Comparison of the rates of infectious keratitis between the groups [ Time Frame: 1 day ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Comparison of the rates of infectious keratitis between the groups [ Time Frame: 1 week ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Comparison of the rates of infectious keratitis between the groups [ Time Frame: 2 weeks ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Comparison of the rates of infectious keratitis between the groups [ Time Frame: 1 month ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Comparison of the rates of infectious keratitis between the groups [ Time Frame: 3 months ]
    This visits will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Comparison of the rates of infectious keratitis between the groups [ Time Frame: Every to 2-4 months depending on the judgment of the surgeon for at least 5 years ]
    These visits will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Comparison of the rates of extrusion of the KPro between the groups [ Time Frame: 1 day ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Comparison of the rates of extrusion of the KPro between the groups [ Time Frame: 1 week ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Comparison of the rates of extrusion of the KPro between the groups [ Time Frame: 2 weeks ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Comparison of the rates of extrusion of the KPro between the groups [ Time Frame: 1 month ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Comparison of the rates of extrusion of the KPro between the groups [ Time Frame: 3 months ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Comparison of the rates of extrusion of the KPro between the groups [ Time Frame: Every to 2-4 months depending on the judgment of the surgeon for at least 5 years ]
    These visits will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Comparison of the visual acuity between the groups [ Time Frame: 1 day ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Comparison of the visual acuity between the groups [ Time Frame: 1 week ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Comparison of the visual acuity between the groups [ Time Frame: 2 weeks ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Comparison of the visual acuity between the groups [ Time Frame: 1 month ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Comparison of the visual acuity between the groups [ Time Frame: 3 months ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
  • Comparison of the visual acuity between the groups [ Time Frame: Every to 2-4 months depending on the judgment of the surgeon for at least 5 years ]
    This visit will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Corneal Collagen Crosslinking to Increase the Resistance of the Support Graft of the KPro Type I Against Corneal Melting
Official Title  ICMJE Corneal Collagen Crosslinking to Increase the Resistance of the Graft Used as a Support for the Boston Keratoprosthesis Type I Against Corneal Melting
Brief Summary The purpose of this study is to demonstrate the safety and efficacy of the corneal collagen crosslinking with riboflavin and ultraviolet A in aim to increase the resistance of the graft used as a support for the Boston keratoprosthesis (KPro) type I against corneal melting (keratolysis or sterile necrosis).
Detailed Description

The Boston type 1 keratoprosthesis (KPro) is an artificial cornea that restores the clarity of the visual axis. It is indicated in patients for whom conventional corneal transplantation offers a very low probability of success. Several innovations have led to improved outcomes following implantation of a KPro. However, retention of the KPro varies between 83 and 100% in the most recent series. The extrusion of the KPro is usually caused by the melting of the corneal tissue (keratolysis or sterile necrosis) used as a support.

This corneal melting is mediated by enzymes from the class of the matrix metalloproteinases (MMP). Several different types of insults may lead to an excess of these enzymes. Chronic inflammation of the ocular surface is undoubtedly the best recognized risk factor. Indeed, autoimmune diseases such as Stevens-Johnson syndrome, Lyell syndrome (toxic epidermal necrolysis, TENS) and mucous membrane pemphigoid, has the highest rate of corneal melting post KPro. Moreover, the development of a retroprosthetic membrane has recently been recognized as a risk factor for melting. Furthermore, the dryness of the corneal epithelium, due to insufficient tear production or an alteration of the blink reflex of the eye, can also lead to an overexpression of MMP. Finally, infectious keratitis can lead to significant thinning of the corneal tissue, even once the infectious process is resolved.

Corneal collagen cross-linking is a technique approved by Health Canada for strengthening the biomechanical properties of the cornea. The crosslinked corneas become more resistant to collagenase and other MMP. The use of a crosslinked corneal graft as a support for the KPro is an interesting approach to the prevention of corneal melting.

A prospective, randomized, controlled and double-blind study will be conducted with patients receiving a Kpro at the Centre Hospitalier de l'Université de Montréal. Forty patients will be randomized into two groups, half will receive KPro in a crosslinked graft-support, while the other half will receive a usual graft-support. Patients will be met by their surgeon to discuss the risks, benefits of the KPro type I and alternatives treatments. Patients accepting KPro surgery, will be informed of the nature and course of the study and will be offered to participate in the study. The Eye bank of Canada will manage the randomization and maintain the codes identifying the crosslinked corneas from the untreated corneas, keeping both the surgeon and the patient blinded. Randomization will be done through a free application (http://www.randomizer.org/form.htm). A series of 10 numbers will be generated. Even numbers indicate crosslinked corneas and odd numbers indicate non-crosslinked corneas. The order of the digits will increase as for each subject is enrolled in the study. The procedure for corneal collagen crosslinking will be performed at the Eye Bank of Canada in a similar procedure to the treatment for keratoconus. Under sterile conditions, the corneo-scleral button will be inspected to meet the standard of care. If the patient is randomized to the crosslinked group, then the cornea will be treated with crosslinking as described further. If the patient is randomized the control group, the cornea will not be treated with crosslink but will be deepithelialized and soaked with riboflavin drops as described further.

The surgeon will receive the graft and operate according to the standard procedure. The KPro surgery and postoperative care will be performed in the standard way and thus will be the same for both study groups. Postoperative follow will be held at 1 day, 1 week, 2 weeks, 1 month and 3 months and will continue subsequently every 2-4 months depending on the judgment of the surgeon. These visits will include measurement of visual acuity and intraocular pressure and a full slit-lamp examination. In particular, the presence of corneal melting, leakage of aqueous humor, corneal infection and extrusion will be noted. Meanwhile, an imaging allowing quantification of the thickness of the cornea graft-support (optical coherence tomography anterior segment) will be performed at least once during the first three months postoperative. This imaging will be repeated at 1, 2 and 5 years.

The prevalence of various complications (melting, leak, infection, extrusion) will be compared between the two groups with the Fischer exact test. Also, the time between surgery and the occurrence of complications will be compared using the Student t test. Finally, survival analysis of Kaplan-Meier will be performed for 1) the occurrence of corneal melting and 2) maintaining a visual acuity greater than 20/200.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Corneal Melting in Boston Keratoprosthesis Type I
Intervention  ICMJE
  • Procedure: Crosslinking with riboflavin of the corneal graft-support
    Corneal graft support for the KPro will be crosslinked and used with the standard surgical technique
  • Procedure: De-epithelisation of the corneal graft support with instillation of riboflavin
    Corneal graft-support will be de-epithelialized and soaked with riboflavin and then used with the standard surgical technique
Study Arms  ICMJE
  • Experimental: Kpro with crosslinked graft-support
    Patient will receive a crosslinked corneal graft-support for the KPro type I. Under sterile conditions, the corneo-scleral button will be inspected, then placed on an artificial anterior chamber. The epithelium of the donor will be removed mechanically. Then one drop of riboflavin 0.1%/dextran 20% will be applied to 3 minutes on the de-epithelialized cornea for 15 minutes. Then, the source of ultraviolet A (UVA) will be irradiating the cornea for 30 minutes with a wavelength of 370 nanometer(nm) length with 5.4 joules(J)/ square centimeter (cm2) and 3 milliwatts(mW)/cm2. Meanwhile, the instillation of a drop of 0.1% riboflavin/dextran 20% continues every 5 minutes. Goggles against UVA are mandatory. The crosslinked graft-support will be forwarded to the surgeon according to standard procedure.
    Intervention: Procedure: Crosslinking with riboflavin of the corneal graft-support
  • Active Comparator: KPro with normal graft-support
    Patient wil receive a normal graft-support for the KPro type I. Under sterile conditions, the corneo-scleral button will be inspected, then placed on an artificial anterior chamber. The epithelium of the donor will be removed mechanically. Then, one drop of riboflavin 0.1% / dextran 20% will be applied to 30 secondes for 5 minutes on the de-epithelialized cornea.The minimally manipulated normal graft-support will be forwarded to the surgeon according to standard procedure.
    Intervention: Procedure: De-epithelisation of the corneal graft support with instillation of riboflavin
Publications * Davis SA, Bovelle R, Han G, Kwagyan J. Corneal collagen cross-linking for bacterial infectious keratitis. Cochrane Database Syst Rev. 2020 Jun 17;6:CD013001. doi: 10.1002/14651858.CD013001.pub2.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 1, 2017)
40
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE January 2024
Estimated Primary Completion Date January 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Candidate for KPro type I
  • Capacity to give written consent
  • Ability to be followed for the duration of the study

Exclusion Criteria:

  • Participation in another interventional study
  • Failure to wear a therapeutic contact lens due to abnormalities of the eyelids.
  • Inability to give written consent

Contraindications to the KPro type I:

  • Severe dryness with keratinization of the ocular surface
  • Intraocular tumor
  • Terminal glaucoma
  • Inoperable retinal detachment
  • Phthisis bulbi
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Marie-Catherine Tessier 514-890-8000 ext 11550 marie-catherine.tessier.chum@ssss.gouv.qc.ca
Contact: Soumaya Bouhout 514-264-0436 soumiya.bouhout@gmail.com
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03041883
Other Study ID Numbers  ICMJE CE14.362
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Marie-Claude Robert, Centre hospitalier de l'Université de Montréal (CHUM)
Study Sponsor  ICMJE Marie-Claude Robert
Collaborators  ICMJE
  • Centre hospitalier de l'Université de Montréal (CHUM)
  • Maisonneuve-Rosemont Hospital
Investigators  ICMJE
Principal Investigator: Marie-Claude Robert, MD Centre hospitalier de l'Université de Montréal (CHUM)
PRS Account Centre hospitalier de l'Université de Montréal (CHUM)
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP